Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Residual Disease in a Novel Xenograft Model of RUNX1-Mutated, Cytogenetically Normal Acute Myeloid Leukemia.

PloS one - 1 Jan 2015

Sivagnanalingam Umayal, Balys Marlene, Eberhardt Allison, Wang Nancy, Myers Jason R, Ashton John M, Becker Michael W, Calvi Laura M, Mendler Jason H

Abstract excerpt

Cytogenetically normal acute myeloid leukemia (CN-AML) patients harboring RUNX1 mutations have a dismal prognosis with anthracycline/cytarabine-based chemotherapy. We aimed to develop an in vivo model of RUNX1-mutated, CN-AML in which the nature of residual disease in this molecular disease subset could be explored. We utilized a well-characterized patient-derived, RUNX1-mutated CN-AML line (CG-SH). Tail vein...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anthracyclines
Share to Bone Marrow

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Core Binding Factor Alpha 2 Subunit

Share to Cytarabine

Share to Cytogenetic Analysis

Share to Mice, Inbred NOD

Share to Mice, SCID

Share to Neoplasm, Residual

Source

Open in PubMed Open full text

Identifiers

PMID: 26177509
DOI: 10.1371/journal.pone.0132375
PMCID: PMC4503761

Genes

RUNX1
ASXL1
GATA2
SETBP1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Residual Disease in a Novel Xenograft Model of RUNX1-Mutated, Cytogenetically Normal Acute Myeloid Leukemia.PMID 26177509Read ↗

Human <i>CEBPA</i> -N AML exhibits enhanced engraftment and a C/EBP <i>α</i> -p30-driven leukemic stem cell programSemantic proximity Read ↗

A platform of robust patient-derived leukemia models covering subgroups for which no cell lines existSemantic proximity Read ↗

Targeting RUNX1 in acute myeloid leukemia: preclinical innovations and therapeutic implications.Semantic proximity Read ↗

Monitoring of residual disease by next-generation deep-sequencing of RUNX1 mutations can identify acute myeloid leukemia patients with resistant disease.Semantic proximity Read ↗

RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.Semantic proximity Read ↗

RUNX1 and cancerSemantic proximity Read ↗

Impact of RUNX1 mutations at distinct sites on the clinical characteristics and prognosis of patients with acute myeloid leukemia.Semantic proximity Read ↗

The influence of mutational status and biological characteristics of acute myeloid leukemia on xenotransplantation outcomes in NOD SCID gamma mice.Semantic proximity Read ↗

Gatekeeper function of the RUNX1 transcription factor in acute leukemia.Semantic proximity Read ↗

RNA sequencing as an alternative tool for detecting measurable residual disease in core-binding factor acute myeloid leukemia.Semantic proximity Read ↗

Allogeneic stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: a study on behalf of the acute leukemia working party of the EBMT.Semantic proximity Read ↗

The ASXL1-G643W variant accelerates the development of CEBPA mutant acute myeloid leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.